University of Wisconsin - Carbone Cancer Center

University of Wisconsin Health

Madison, WI

Website

(888) 828-2206 Refer Patient

Filters

Help Me Find Trials

Sort by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma

Learn more

CAR T Cell
GPRC5D
Phase 2

Accepting patients

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Learn more

CELMoD
Randomization
Phase 3

Get personalized results in 60 seconds

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.

Help me find trials

Accepting patients

DREAMM9

A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma

Learn more

Antibody Drug Conjugate (ADC)
BCMA
Randomization
Phase 1

Accepting patients

DREAMM5

Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Learn more

Antibody Drug Conjugate (ADC)
Gamma-Secretase Inhibitor
BCMA
Phase 2
Has results

Accepting patients

Molecular Profiling

An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Learn more

Genetic Sequencing

Accepting patients

Early Detection Blood Tests

Blinded Reference Set for Multicancer Early Detection Blood Tests

Learn more

Observational Trial

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Learn more

Monoclonal Antibody
CD38
Maintenance
Phase 3

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Learn more